Rajesh Malik Net Worth

The estimated Net Worth of Rajesh Malik is at least $2.62 Milion dollars as of 5 July 2024. Rajesh Malik owns over 2,475 units of G1 Therapeutics Inc stock worth over $1,135,895 and over the last 7 years he sold GTHX stock worth over $91,862. In addition, he makes $1,388,360 as Chief Medical Officer i Senior Vice President - Research and Development at G1 Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rajesh Malik GTHX stock SEC Form 4 insiders trading

Rajesh has made over 36 trades of the G1 Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,475 units of GTHX stock worth $6,212 on 5 July 2024.

The largest trade he's ever made was exercising 33,839 units of G1 Therapeutics Inc stock on 11 December 2023 worth over $12,182. On average, Rajesh trades about 6,859 units every 58 days since 2018. As of 5 July 2024 he still owns at least 159,312 units of G1 Therapeutics Inc stock.

You can see the complete history of Rajesh Malik stock trades at the bottom of the page.

Rajesh Malik biography

Dr. Rajesh K. Malik M.D. serves as Chief Medical Officer, Senior Vice President - Research and Development of the Company. Prior to becoming our Chief Medical Officer, Dr. Malik served as a consultant for business, clinical and regulatory matters from May 2013 through July 2014, including as a consultant to our Company from July 2013 to June 2014. Prior to joining us, Dr. Malik served as Chief Medical Officer of Agennix AG, a German biotechnology company, from January 2007 to September 2013, and as a member of the management board of Agennix AG from November 2009 to September 2013. Dr. Malik also served as Chief Medical Officer of Adherex Technologies, Inc., a biopharmaceutical company, from September 2004 to January 2007. Dr. Malik also served as an attending physician at the University of Virginia Medical Center and on the faculty of the University of Virginia School of Medicine. Dr. Malik earned his M.B. and Ch.B. from the University of Sheffield Medical School.

What is the salary of Rajesh Malik?

As the Chief Medical Officer i Senior Vice President - Research and Development of G1 Therapeutics Inc, the total compensation of Rajesh Malik at G1 Therapeutics Inc is $1,388,360. There are 6 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.

How old is Rajesh Malik?

Rajesh Malik is 61, he's been the Chief Medical Officer i Senior Vice President - Research and Development of G1 Therapeutics Inc since 2018. There are 6 older and 18 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.

What's Rajesh Malik's mailing address?

Rajesh's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.

Insiders trading at G1 Therapeutics Inc

Over the last 8 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman oraz Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.

What does G1 Therapeutics Inc do?

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.

Complete history of Rajesh Malik stock trades at G1 Therapeutics Inc

G1 Therapeutics Inc executives and stock owners

G1 Therapeutics Inc executives and other stock owners filed with the SEC include:

• Mark Avagliano,
  Chief Business Officer
• James Hanson,
  General Counsel, Secretary
• Mark Velleca,
  President, Chief Executive Officer, Director
• Terry Murdock,
  Chief Operating Officer
• Garry Nicholson,
  Independent Chairman of the Board
• Jennifer Moses,
  Chief Financial Officer
• Rajesh Malik,
  Chief Medical Officer, Senior Vice President - Research and Development
• Dr. Mark A. Velleca M.D., Ph.D.,
  Sr. Advisor & Director
• Mark Avagliano,
  Chief Bus. Officer
• Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
  Chief Medical Officer and Sr. VP of R&D
• Dr. Rajesh K. Malik,
  Chief Medical Officer and Sr. VP of R&D
• Andrew Perry,
  Chief Commercial Officer
• Jennifer K. Moses CPA,
  Chief Financial Officer
• Jennifer K. Moses,
  Chief Financial Officer
• Seth Rudnick,
  Independent Director
• Glenn Muir,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Fredric Eshelman,
  Independent Director
• Willie Deese,
  Independent Director
• Andrew Witty,
  Independent Director
• John Bailey,
  Independent Director
• Soma Gupta,
  Chief Commercial Officer
• Jay Strum,
  Chief Scientific Officer
• Terry L. Murdock,
  Chief Operating Officer
• Blake Jensen,
  VP of Quality & Compliance
• William C. Roberts,
  VP of Investor Relations & Corp. Communications
• Dr. Jay C. Strum,
  Chief Scientific Officer
• Alexander D. Smith M.S.,
  VP of Technical Operations
• John E. Bailey Jr.,
  CEO, Pres & Director
• Clay Hatteras Venture Advis...,
  
• Capital Management, L.P.Ra ...,
  
• Christy L Shaffer,
  Director
• Ventures, Inc. Med Immune,
  10% owner
• Ventures, Llc Eshelman,
  10% owner
• Clay Hatteras Venture Advis...,
  
• Barclay A Phillips,
  SVP & Chief Financial Officer
• Monica R. Thomas,
  Chief Legal & People Officer
• Jacks Lee,
  
• John Demaree,
  Chief Commercial Officer
• Alicia Secor,
  
• Cynthia Louise Flowers,
  
• Andrew Perry,
  Chief Commercial Officer
• Norman Sharpless,
  
• John W. V Umstead,
  Chief Financial Officer